Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023-38.
Mäkinen H, Kaarela K, Huhtala H, Hannonen PJ, Korpela M, Sokka T. Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis? Ann Rheum Dis 2012; 72-5.
Willemze A, Toes REM, Huizinga TWJ, Trouw LA. Trouw: new biomarkers in rheumatoid arthritis Netherlands J of Med 2012; 7: 9
Dawson B, Trapp R. Basic and Clinical Biostatistics 4th Edition, New York, United States Mcgraw-Hill Medical Publishing Inc 2004; 23(61): 245.
Maksymowych WP, Marotta A. 14-3-3η: a novel mediator upregulated by TNFα, reflects clinical response to anti-TNFα therapy. Arthritis Rheum 2011; (63): (Suppl. 10): S162-3.
Othman MA, Wan WS, Ghazal M. Hamid WZWA, Won KK, Yahya NK. Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor. Saudi Med J 2017; 38-9.
Kucuksahin BO, Yeşil TH, Akan S, Erten S. Sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2018; 77-2.
Novikov A, Aleksandrova E, Cherkasova M, et al. diagnostic value of 14-3-3 (eta) in rheumatoid arthritis. Annals of The Rheum Dis 2017; 76:(Suppl 2).
Dasgupta B, Cherkas Y, Lamberth S, et al. Serum 14-3-3 ETA is an RA specific mechanistic marker. J Rheumatol 2014; 41(11): 2104.
Serum level of 14-3-3η (eta) protein as a diagnostic marker for rheumatoid arthritis and potential correlation with disease activity. MOJ Orthop Rheumatol 2018; 7-4.
Zickuhr L, Pourpaki M, Brooks MM, Joseph A. 14-3-3η: Useful for more than the diagnosis of rheumatoid arthritis? Arthritis Rheumatol 2017; 69: (suppl 10)
Schaardenburg DV, Turk S, Bores M, Walter M. 14-3-3η is an independent predictor of radiographic changes in early RA and higher titers inform a higher likelihood of joint damage progression. Ann Rheum Dis 2014; 73(Suppl. 2): 266.
Berglin E, Hallmans G. Serum 14-3-3η predicts the risk of RA development and its higher titers are associated with higher risk. Ann Rheum Dis 2014; 73.
Chao R, Das M, Purat N, et al. 14–3–3eta positivity is associated with higher rheumatoid arthritis disease activity measured by multi-biomarker disease activity assay. Ann Rheum Dis 2018; 77: 1326-7.
Yee A, Webb T, Seaman A, et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res 2015; 61: 24-30.
Jagpal A, Navarro-Millan I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment, and treatment Jagpal and Navarro-Millán BMC Rheumatol 2018; 2(10)